marcello106 schreef op 4 januari 2011 18:52:
Tue 04 Jan 2011
Harlow, UK; 4 January 2011 – Argenta today announced that it has entered into a drug discovery collaboration with Dr. Reddy’s Laboratories Ltd. (NYSE:RDY) in the area of pain and inflammation.
Argenta will apply its integrated drug discovery platform and expertise for hit-to-lead and lead optimization on multiple Dr. Reddy’s discovery targets in pain and inflammation. The aim of the collaboration is to deliver high quality development candidates to support Dr. Reddy’s research efforts for proprietary products.
Dr. John Montana, Managing Director of Argenta, commented: “We are excited to be working with Dr. Reddy’s in identifying novel and differentiated drug candidates for multiple targets meeting unmet clinical needs in pain and inflammation”.
About Argenta
Argenta’s contract research, which includes expertise in medicinal chemistry, computer-aided drug discovery, in vitro biology, analytics, in vivo pharmacokinetics, pharmacology and world-leading respiratory models, has a strong reputation for scientific excellence. Argenta is a service division of Galapagos NV (Euronext: GLPG) and employs over 140 people in the UK with its main operations in Harlow. More info at:
www.argentadiscovery.com CONTACTS
Argenta
John Montana, Managing Director
+44 (0)1279 645647
john.montana@glpg.com This release may contain forward-looking statements, including, without limitation, statements containing the words “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “will,” “could,” “stands to,” and “continues,” as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
Back to listing
Innovation. Expertise. Delivered .